DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Celecoxib in Treating Patients With Early-Stage Rectal Cancer

Information source: Vanderbilt-Ingram Cancer Center
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Colorectal Cancer

Intervention: celecoxib (Drug); gene expression analysis (Genetic); protein expression analysis (Genetic); immunohistochemistry staining method (Other); laboratory biomarker analysis (Other); mass spectrometry (Other); biopsy (Procedure); neoadjuvant therapy (Procedure); therapeutic conventional surgery (Procedure)

Phase: N/A

Status: Terminated

Sponsored by: Vanderbilt-Ingram Cancer Center

Official(s) and/or principal investigator(s):
A. Bapsi Chakravarthy, MD, Principal Investigator, Affiliation: Vanderbilt-Ingram Cancer Center


RATIONALE: Studying samples of tissue, blood, and urine from patients with cancer in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how rectal cancer will respond to treatment with celecoxib. PURPOSE: This clinical trial is studying how well celecoxib works in treating patients with early-stage rectal cancer.

Clinical Details

Official title: Pilot COX-2 Activity in Early Stage Rectal Cancer -Short Term Administration of Celecoxib (SPORE)

Study design: Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Event rate of over-expression of cyclooxygenase-2

Percent change of eicosanoid level

Percent change of VEGF and prostaglandin-M levels

Change of gene and protein expression pattern from pre- to post-treatment levels

Detailed description: OBJECTIVES:

- Determine cyclooxygenase-2 (COX-2) over-expression in tumor specimens from patients

with early-stage rectal cancer.

- Determine whether administration of a COX-2 inhibitor, celecoxib, results in changes in

tumor (COX-2 overexpressing) levels of eicosanoids but not in levels in the surrounding normal tissue that is expected not to express COX-2.

- Determine whether surrogate markers of eicosanoid metabolism (i. e., serum VEGF levels,

tumor prostaglandin E_2 [PGE_2], and the major urinary metabolite of PGE_2 [PGE-M]) in biological specimens from these patients correlate with changes noted in tumor tissue.

- Determine if there is a greater change in protein and gene expression from pretreatment

biopsy levels in patient tumor specimens (COX-2 overexpressing) vs specimens of surrounding normal tissue (expected not to be COX-2 overexpressing). OUTLINE: Patients receive oral celecoxib twice daily on days 1-5. Patients then undergo planned local excision or definitive radical resection on day 6. Tumor tissue and normal tissue (at least 5 cm away from the tumor) samples are collected pretreatment. Post-treatment tissue samples are collected along with the surgery. Serum and urine samples are obtained at baseline and after administration of celecoxib. Tumor and normal tissue specimens are analyzed by assays measuring markers of cyclooxygenase-2 (COX-2) activity (i. e., COX-2 mRNA and protein, tumor prostaglandin E_2 [PGE_2], and VEGF). Tissue samples are also assessed by cDNA microarray and imaging mass spectrometry to determine overall changes in gene and protein expression from pretreatment levels. Surrogate markers of COX-2 activity in serum (i. e., VEGF) and urine (i. e., urinary metabolite of PGE_2 [PGE-M]) are also assessed and compared with changes noted in tumor tissue. COX-2 protein levels are determined by immunohistochemistry in patients with limited pretreatment tumor tissue specimens.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Clinical diagnosis of primary adenocarcinoma of the rectum (to be histologically

confirmed upon study entry)

- Tumor must be at or below the peritoneal reflection

- The distal border of the tumor is within 12 cm of the anal verge on proctoscopic


- Clinically resectable disease


- Karnofsky performance status 60-100%

- WBC ≥ 4,000/mm³

- Platelet count ≥ 150,000/mm³

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No other serious medical illness (other than rectal cancer) that would preclude study


- No psychiatric condition that would preclude informed consent

- No history of allergy to celecoxib or any other NSAIDs, including acetylsalicylic

acid (i. e., aspirin), ibuprofen, or indomethacin

- No history of allergy to sulfonamides

Exclusion criteria: Not noted PRIOR CONCURRENT THERAPY:

- At least 7 days since prior and no concurrent NSAIDs or other cyclooxygenase-2


- No concurrent warfarin, except low-dose warfarin (i. e., 1 mg/day) administered for


Locations and Contacts

Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232, United States

Veterans Administration, Nashville, Tennessee 37212, United States

Additional Information

Starting date: July 2002
Last updated: March 2, 2013

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017